JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology
Abstract Juvenile Idiopathic Inflammatory Myopathies (IIM) are a group of rare diseases that are heterogeneous in terms of pathology that can include proximal muscle weakness, associated skin changes and systemic involvement. Despite options for treatment, many patients continue to suffer resistant...
Saved in:
Main Authors: | Meredyth G. Ll Wilkinson (Author), Claire T. Deakin (Author), Charalampia Papadopoulou (Author), Despina Eleftheriou (Author), Lucy R. Wedderburn (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Juvenile dermatomyositis (JDM) sine myositis
by: Schulz A, et al.
Published: (2011) -
Characterising inflammatory markers in two childhood autoimmune diseases (JIA and JDM) pre and post methotrexate
by: Patrick F, et al.
Published: (2011) -
Calcinosis as a complication of juvenile dermatomyositis (JDM)
by: Luz Contreras, et al.
Published: (2011) -
What is the mortality of Juvenile Dermatomyositis (JDM) in the modern treatment era
by: Smith S, et al.
Published: (2008) -
Muscle MRI at the time of questionable disease flares in Juvenile Dermatomyositis (JDM)
by: Rabheh Abdul-Aziz, et al.
Published: (2017)